8-K: TransCode & Quantum Leap Launch Phase 2a Trial

TransCode Therapeutics partners with Quantum Leap Healthcare Collaborative to advance its lead candidate, TTX-MC138, into a Phase 2a clinical trial for colorectal cancer.

Summary

• TransCode Therapeutics (NASDAQ: RNAZ) announced a new collaboration with Quantum Leap Healthcare Collaborative.
• The collaboration will evaluate TransCode's lead therapeutic candidate, TTX-MC138, as part of the Quantum Leap PRE-I-SPY clinical trial platform.
• A Phase 2a dose-expansion clinical trial will enroll up to 45 patients with colorectal cancer who have completed standard curative-intent therapy and are ctDNA positive.
• The Phase 2a portion of the trial is planned to begin in the first half of 2026 and will be led by Principal Investigator Dr. Paula Pohlmann of MD Anderson Cancer Center.
• The trial aims to evaluate the biological and clinical activity of TTX-MC138 in the Minimal Residual Disease (MRD) setting.
• The decision to proceed with Phase 2a testing is based on positive safety and durable clinical benefit observed in TransCode's Phase 1a trial.
• TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b (miR-10b), a microRNA believed to be critical to the emergence and progression of many metastatic cancers.

Sentiment

Score: 8

Explanation: The announcement of a successful Phase 1a trial and the progression to a Phase 2a trial in collaboration with a respected entity like Quantum Leap is a significant positive milestone for a clinical-stage biotech company. It addresses a high unmet medical need and suggests promising early data, despite the inherent risks of drug development.

Positives

• Successful completion of the Phase 1a trial, achieving its primary safety endpoint and establishing a recommended Phase 2 dose.
• Observed safety profile and durable anti-tumor effects of TTX-MC138 are particularly encouraging.
• Collaboration with Quantum Leap Healthcare Collaborative and inclusion in the PRE-I-SPY clinical trial platform is expected to accelerate development.
• The trial addresses a significant unmet medical need in patients with minimal residual disease (MRD) colorectal cancer who are ctDNA positive and at high risk of recurrence.
• TTX-MC138 offers a therapeutic option with a mechanism of action specifically targeting metastatic disease combined with an excellent safety profile, potentially allowing earlier intervention.

Risks

• Risks associated with drug discovery and development.
• Risk that the results of clinical trials will not be consistent with preclinical studies, expectations, or results from previous clinical trials.
• Risks associated with the conduct of clinical trials.
• Risks associated with TransCode's financial condition and its need to obtain additional funding to support its business activities, including its ability to continue as a going concern.
• Risks associated with the timing and outcome of planned regulatory submissions.
• Risks associated with obtaining, maintaining, and protecting intellectual property.
• Risks associated with TransCode's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties.
• Risks of competition from other companies developing products for similar uses.
• Risks associated with TransCode's dependence on third parties.
• Risks associated with geopolitical events and pandemics, including the COVID-19 coronavirus and military actions.

Future Outlook

The company plans to initiate a Phase 2a dose-expansion clinical trial for TTX-MC138 in the first half of 2026, aiming to evaluate its biological and clinical activity in the minimal residual disease setting for colorectal cancer patients. The collaboration with Quantum Leap is expected to accelerate the program, with the goal of advancing effective, less toxic precision therapies into Phase 2 and beyond.

Management Comments

• "The safety and durable clinical benefit observed in TransCode's Phase 1a trial with TTX-MC138 provide the basis for TransCode's decision to proceed with Phase 2a clinical testing." Daniel Vlock, MD, TransCode's Consulting Clinician.
• "The observed safety profile, coupled with the durability of TTX-MC138's anti-tumor effects, is particularly encouraging. These findings are consistent with the drug's mechanism of action and provide a basis for a more rigorous efficacy evaluation. This positions us to potentially intervene earlier in the patient's disease, offering a new therapeutic option for patients at risk of developing metastatic disease." Daniel Vlock, MD.
• "Detecting and treating micrometastatic disease before it becomes visible is one of the biggest unmet challenges in cancer." Laura Esserman, M.D., co-founder of Quantum Leap.
• "The PRE-ISPY Trial is uniquely positioned to rapidly evaluate agents like TTX-MC138 that may eradicate minimal residual disease and prevent recurrence in colorectal and eventually other cancer. We are excited to collaborate with TransCode to accelerate this program, with the goal of advancing effective, less toxic precision therapies into Phase 2 and beyond where the potential to truly cure patients exists." Laura Esserman, M.D.

Industry Context

The collaboration addresses a critical unmet need in oncology: treating minimal residual disease (MRD) to prevent cancer recurrence and metastasis. The PRE-I-SPY platform, an extension of the I-SPY Trials, represents an innovative, collaborative model involving regulatory bodies, industry, patient advocates, and clinicians to rapidly screen and advance promising experimental treatments, which is a significant trend in accelerating drug development for complex diseases like cancer.

Comparison to Industry Standards

• The I-SPY Trials, sponsored by Quantum Leap Healthcare Collaborative, are highlighted as a unique collaboration among the U.S. FDA, industry partners, patient advocates, philanthropic sponsors, and clinicians across leading U.S. cancer research centers, setting a benchmark for accelerated drug development models.
• The PRE-I-SPY platform extends this model into early feasibility testing, aiming to accelerate biologically targeted therapies into high-risk curative settings, representing an advanced approach compared to traditional linear trial designs.
• The focus on minimal residual disease (MRD) and ctDNA positive patients in colorectal cancer positions TTX-MC138 in a high-need area, aligning with industry efforts to develop precision therapies for early intervention and prevention of recurrence.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to positive clinical trial progression and accelerated development, but also exposure to risks inherent in drug development and potential future dilution from capital raises.
• Patients: Offers a new potential therapeutic option for colorectal cancer patients with minimal residual disease who currently lack effective treatments to prevent recurrence.
• Medical Community: Contributes to advancing research in oncology, particularly in the challenging area of micrometastatic disease and precision therapies.
• Employees: Positive news for company morale and stability, potentially attracting new talent.

Next Steps

• Initiation of the Phase 2a dose-expansion clinical trial for TTX-MC138 in the first half of 2026.
• Evaluation of biological and clinical activity of TTX-MC138 in the Minimal Residual Disease (MRD) setting.
• Potential advancement of TTX-MC138 into further clinical phases if successful.

Key Dates

Recommendation

While the advancement to Phase 2a and the collaboration are significant positive developments for a clinical-stage biotech, the company is still in early-stage clinical trials with no commercial products. The inherent risks of drug development, including the need for future funding and the uncertainty of trial outcomes, warrant a 'hold' recommendation for most investors. A 'buy' might be considered by high-risk tolerant investors who believe in the long-term potential of the technology, but a 'hold' acknowledges the positive progress while recognizing the substantial remaining hurdles and risks.

Keywords

TransCode Therapeutics, Quantum Leap Healthcare Collaborative, TTX-MC138, PRE-I-SPY, clinical trial, Phase 2a, colorectal cancer, ctDNA positive, minimal residual disease, MRD, microRNA-10b, miR-10b, metastatic cancer, oncology, RNA therapeutics, RNAZ